Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Progenitor Cell Mobilisation

A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents

Bone Marrow Transplantation volume 32, pages 1113–1117 (2003)Cite this article

Summary:

High-dose chemotherapy and autologous stem cell rescue is considered a standard part of initial therapy for patients with multiple myeloma. Therefore, potential transplant candidates are generally treated with dexamethasone-based programs rather than alkylating agents to avoid stem cell toxicity. The optimal mobilizing regimen for patients with multiple myeloma has not been defined. However, aggressive chemotherapy may result in excessive morbidity and cost in this older, immunocompromised population. We retrospectively examined our experience with a well-tolerated regimen of 1.5 g/m2 cyclophosphamide on day −10 followed by 10 μg/kg G-CSF beginning on day −7 in 50 consecutive patients with multiple myeloma and no prior alkylating agent therapy. Median stem cell collection was 4.88 × 106 CD34+ cells/kg per apheresis and 44 patients collected >5 × 106 CD34+ cells/kg within 2 days. In 36 patients, more than 10 × 106 CD34+ cells/kg were collected including 33 patients who required 1–2 days of collection. One patient required hospitalization for fever/neutropenia and two required weekend apheresis. We conclude that 1.5 g/m2 cyclophosphamide plus 10 μg/kg G-CSF is a safe, effective, highly predictable mobilizing program that uniformly provided enough stem cells for one transplant and enough stem cells for two transplants.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  Google Scholar 

  2. Attal M, Harousseau JL, Facon T et al. Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective study of the ‘Intergroupe Francophone du Myeloma’ (IFM 94). Am Soc Hematol 2002; 100: 5a–6a, (Abstract).

    Google Scholar 

  3. Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319–4323.

    Article  CAS  Google Scholar 

  4. Weber D, Rankin K, Gavino M et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19.

    Article  CAS  Google Scholar 

  5. Boccadoro M, Palumbo A, Bringhen S et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002; 87: 846–850.

    CAS  PubMed  Google Scholar 

  6. Desikan KR, Barlogie B, Jagannath S et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 16: 1547–1553.

    Article  CAS  Google Scholar 

  7. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65.

    CAS  Google Scholar 

  8. Jones HM, Jones SA, Watts MJ et al. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. J Clin Oncol 1994; 12: 1693–1702.

    Article  CAS  Google Scholar 

  9. Desikan KR, Tricot G, Munshi NC et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol 2001; 112: 242–247.

    Article  CAS  Google Scholar 

  10. Mohle R, Murea S, Pforsich M et al. Estimation of the progenitor cell yield in a leukapheresis product by previous measurement of CD34+ cells in the peripheral blood. Vox Sanguinis 1996; 71: 90–96.

    Article  CAS  Google Scholar 

  11. Corso A, Arcaini L, Caberlon S et al. A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. Haematologica 2002; 87: 1041–1045.

    CAS  PubMed  Google Scholar 

  12. Lazzarino M, Corso A, Barbarano L et al. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 2001; 28: 835–839.

    Article  CAS  Google Scholar 

  13. Jantunen E, Putkonen M, Nousiainen T et al. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347–351.

    Article  CAS  Google Scholar 

  14. Cremer FW, Kiel K, Wallmeier M et al. A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma. Ann Oncol 1997; 8: 633–636.

    Article  CAS  Google Scholar 

  15. Vescio R, Schiller G, Stewart AK et al. Multicenter phase III trial to evaluate CD34(+) selected vs unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999; 93: 1858–1868.

    CAS  Google Scholar 

  16. Barbui AM, Galli M, Dotti G et al. Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. Br J Haematol 2002; 116: 202–210.

    Article  Google Scholar 

  17. Stewart AK, Vescio R, Schiller G et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771–3779.

    Article  CAS  Google Scholar 

  18. Knudsen LM, Rasmussen T, Nikolaisen K et al. Mobilisation of tumour cells along with CD34+ cells to peripheral blood in multiple myeloma. Eur J Haematol 2001; 67: 289–295.

    Article  CAS  Google Scholar 

  19. Cremer FW, Kiel K, Wallmeier M et al. Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone. Exp Hematol 1998; 26: 969–975.

    CAS  Google Scholar 

  20. Ladetto M, Omede P, Sametti S et al. Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests. Exp Hematol 2002; 30: 529–536.

    Article  CAS  Google Scholar 

  21. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864–869.

    CAS  Google Scholar 

  22. Voso MT, Pantel G, Weis M et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109: 729–735.

    Article  CAS  Google Scholar 

  23. Lazzarino M, Arcaini L, Bernasconi P et al. A sequence of immuno-chemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002; 116: 229–235.

    Article  CAS  Google Scholar 

  24. Kroger N, Zeller W, Hassan HT et al. Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. Ann Hematol 1998; 76: 257–262.

    Article  CAS  Google Scholar 

  25. D'Hondt L, Emmons RV, Andre M et al. The administration of 10 μg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed. Leukemia Lymphoma 1999; 34: 105–109.

    Article  CAS  Google Scholar 

  26. Morris CL, Siegel E, Barlogie B et al. Mobilization of CD34+ cells in elderly patients (70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120: 413–423.

    Article  Google Scholar 

  27. Fassas AB, Spencer T, Desikan R et al. Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients. Br J Haematol 2002; 119: 164–168.

    Article  Google Scholar 

  28. Galimberti S, Morabito F, Guerrini F et al. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol 2003; 120: 405–412.

    Article  Google Scholar 

  29. Porrata LF, Gertz MA, Inwards DJ et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579–585.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA

    K A Lerro, E Medoff, S E Seropian & D L Cooper

  2. Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA

    Y Wu, E Snyder & D Krause

Authors
  1. K A Lerro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Medoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S E Seropian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Snyder
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Krause
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D L Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D L Cooper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lerro, K., Medoff, E., Wu, Y. et al. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplant 32, 1113–1117 (2003). https://doi.org/10.1038/sj.bmt.1704286

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704286

Keywords

This article is cited by

Search

Advanced search

Quick links